파이프라인 페이지
Welcome
to
ATGC's
Lab
ATGC is conducting various pharmaceutical research and
development activities based on its successful
commercialization experience of botulinum toxin products.
Through continuous R&D efforts, the company aims to
expand its product portfolio beyond botulinum toxin to
include treatments for osteoarthritis, type 2 diabetes, and
rare disease.
Our
pipeline
| Pipeline | Indication | Basic Research |
Candidate Drug/ Product Discovery |
Non-clinical | Phase 1 Clinical | Phase 2 Clinical | Phase 3 Clinical | Drug/Product Approval |
|
|---|---|---|---|---|---|---|---|---|---|
| Biological Products | ATGC-100 | Frown wrinkles | |||||||
| ATGC-110 | Frown wrinkles | ||||||||
| ATGC-200 | Osteoarthritis | ||||||||
| ATGC-300 | Type 2 Diabetes mellitus | ||||||||
| New drug | |||||||||
ATGC currently has two products nearing commercialization
through its own research and development capabilities and is
planning to expand indications and therapeutic areas.
View
more
Thehighestvalue,
thatisR&D
We
focus
on
what
we
do
best.
-
Core research activities and
process development -
Technology Transfer
-
Licensing
ATGC is responsible for the discovery and
research of the most critical candidates required
for the development and dissemination of
innovative new drugs. We conduct the various
tests and research required to develop medically
valuable products.
Biotechnology, science and technology change
and develop rapidly. We encourage our
employees to learn and develop in order to lead
the way in these changes.
Establishing a virtuous
cycle for sustainable
R&D activities
